Patricia Ashton-Prolla
Overview
Explore the profile of Patricia Ashton-Prolla including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
151
Citations
1750
Followers
0
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Diaz-Gay M, Dos Santos W, Moody S, Kazachkova M, Abbasi A, Steele C, et al.
medRxiv
. 2025 Mar;
PMID: 40034755
Colorectal cancer incidence rates vary geographically and have changed over time. Notably, in the past two decades, the incidence of early-onset colorectal cancer, affecting individuals under the age of 50...
2.
Galante P, Guardia G, Pisani J, Sandoval R, Barros-Filho M, Gifoni A, et al.
Lancet Reg Health Am
. 2025 Feb;
42:100982.
PMID: 39895904
Background: Li-Fraumeni Syndrome (LFS) is a predisposition associated with early onset malignant tumors caused by germline pathogenic variants in the gene. Although rare worldwide, LFS is prevalent in Southern Brazil...
3.
Abreu R, Pereira A, Rosa M, Ashton-Prolla P, Silva V, Melendez M, et al.
Sci Rep
. 2024 Jul;
14(1):17187.
PMID: 39060302
Germline TP53 pathogenic variants can lead to a cancer susceptibility syndrome known as Li-Fraumeni (LFS). Variants affecting its activity can drive tumorigenesis altering p53 pathways and their identification is crucial...
4.
Ashton-Prolla P, Achatz M, Moreira M, Palmero E, de Queiroz Soares D, de Faria Ferraz V, et al.
Rev Assoc Med Bras (1992)
. 2024 Jun;
70(suppl 1):e2024S117.
PMID: 38865537
No abstract available.
5.
Senkin S, Moody S, Diaz-Gay M, Abedi-Ardekani B, Cattiaux T, Ferreiro-Iglesias A, et al.
Nature
. 2024 May;
629(8013):910-918.
PMID: 38693263
International differences in the incidence of many cancer types indicate the existence of carcinogen exposures that have not yet been identified by conventional epidemiology make a substantial contribution to cancer...
6.
Lu Y, Cho T, Mukherjee S, Suarez C, Gonzalez-Foutel N, Malik A, et al.
Mol Syst Biol
. 2024 Apr;
20(6):719-740.
PMID: 38580884
Tumor suppressor p53 (TP53) is frequently mutated in cancer, often resulting not only in loss of its tumor-suppressive function but also acquisition of dominant-negative and even oncogenic gain-of-function traits. While...
7.
Campacci N, Grasel R, Galvao H, Garcia L, Ribeiro P, Pereira K, et al.
Front Psychol
. 2024 Mar;
15:1306388.
PMID: 38500651
Introduction: Cancer Genetic Counseling (CGC) and genetic testing (GT) assume a paramount role for hereditary cancer predisposition syndrome families. We assessed the effects of CGC and GT on women affected...
8.
Garcia A, Viola G, Correa B, Fischer T, Pinho M, Rodrigues G, et al.
Genet Mol Biol
. 2024 Feb;
46(3 Suppl 1):e20230132.
PMID: 38373162
Tuberous Sclerosis Complex (TSC) is caused by loss of function germline variants in the TSC1 or TSC2 tumor suppressor genes. Genetic testing for the detection of pathogenic variants in either...
9.
Perdomo S, Abedi-Ardekani B, de Carvalho A, Ferreiro-Iglesias A, Gaborieau V, Cattiaux T, et al.
Cell Genom
. 2024 Feb;
4(3):100500.
PMID: 38325367
Large-scale biorepositories and databases are essential to generate equitable, effective, and sustainable advances in cancer prevention, early detection, cancer therapy, cancer care, and surveillance. The Mutographs project has created a...
10.
Vieira I, Viola G, Pezzi E, Kowalski T, Fernandes B, Andreis T, et al.
Genet Mol Biol
. 2024 Jan;
46(3 Suppl 1):e20230133.
PMID: 38252059
The TP53 3'UTR variant rs78378222 A>C has been detected in different tumor types as a somatic alteration that reduces p53 expression through modification of polyadenylation and miRNA regulation. Its prevalence...